Imperial et al. invest £50m in Cell Medica

Cell Medica will use the fresh funding to further develop its cellular immunotherapy products. Its lead oncology product, CMD-003, is currently in its phase-II clinical trial.

Imperial committed £15m to the round in exchange for a 27.9% stake in the business. The firm has previously invested in the business, including a seed investment in 2007 and as the lead investor in its series-A round in 2012.

As of July this year, Imperial held a 25.2% stake in the business and had invested a total of £4.8m.

Cell Medica's series-A round took place in July 2012 and saw the company secure £17m from Imperial and Invesco.

Company
Founded in 2006 and headquartered in London, Cell Medica is developing cellular immunotherapy products designed to aid in the treatment of cancer and infectious diseases.

Its CMD-003 product is being tested for treating patients with advanced lymphomas associated with Epstein Barr virus, a virus of the herpes family that is associated with some types of cancer, including Hodgkin's lymphoma and Burkitt's lymphoma.

People
Gregg Sando is the CEO of Cell Medica. Main Bhaman is director of healthcare ventures at Imperial.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Early-stage
• United Kingdom